MiR-4269 suppresses the tumorigenesis and development of pancreatic cancer by targeting ZEB1/OTX1 pathway.


Journal

Bioscience reports
ISSN: 1573-4935
Titre abrégé: Biosci Rep
Pays: England
ID NLM: 8102797

Informations de publication

Date de publication:
26 06 2020
Historique:
received: 09 01 2020
revised: 20 05 2020
accepted: 01 06 2020
pubmed: 3 6 2020
medline: 24 3 2021
entrez: 3 6 2020
Statut: ppublish

Résumé

As one of the most prevalent malignant tumors, pancreatic cancer (PC) is a leading fatal cancer worldwide. Surging evidence has unraveled that miRNAs are involved in the occurrence and progression of multiple cancers, including PC. The tumor suppressor effects of miR-4269 have been certified in gastric carcinoma. However, the potential function of miR-4269 remains largely unclear, which drives us to identify the role of miR-4269 in PC development. In the present study, we determined the expression pattern of miR-4269 in PC cells and normal cells. Results of RT-qPCR analysis illuminated that miR-4269 expression level in PC cells was lower than that in normal cells. Functional assays demonstrated that up-regulation of miR-4269 obviously inhibited the proliferation, migration and invasion of PC cells. In order to elucidate the mechanism governing miR-4269 in PC, we carried out bioinformatics analysis and further experimental investigations. Our results validated that ZEB1 was a direct target of miR-4269. Additionally, ZEB1 activated the transcription of OXT1. More importantly, miR-4269 attenuated the expression level of OXT1 via targeting ZEB1. Ultimately, our findings confirmed that miR-4269 served as a cancer suppressor in PC through regulation of ZEB1/OTX1 pathway, which suggested that miR-4269 might represent a promising target for the clinical treatment of PC.

Identifiants

pubmed: 32484209
pii: 225115
doi: 10.1042/BSR20200010
pmc: PMC7286876
pii:
doi:

Substances chimiques

MIRN4269 microRNA, human 0
MicroRNAs 0
OTX1 protein, human 0
Otx Transcription Factors 0
ZEB1 protein, human 0
Zinc Finger E-box-Binding Homeobox 1 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2020 The Author(s).

Références

Mol Cell Biol. 2004 Jul;24(14):6151-61
pubmed: 15226419
Oncogene. 2017 Nov 23;36(47):6518-6530
pubmed: 28759040
Biochim Biophys Acta. 2015 Jan;1855(1):24-42
pubmed: 25450578
Pancreatology. 2005;5(4-5):316-24; discussion 324
pubmed: 15983443
Int J Oncol. 2016 Apr;48(4):1688-700
pubmed: 26892887
Oncotarget. 2017 Feb 14;8(7):11071-11082
pubmed: 28052003
Development. 1993 Oct;119(2):433-46
pubmed: 7904558
Cancer Metastasis Rev. 2015 Mar;34(1):97-114
pubmed: 25566685
Mod Pathol. 2017 Aug;30(8):1116-1125
pubmed: 28548126
J Korean Med Sci. 2016 Aug;31(8):1215-23
pubmed: 27478331
Acta Pharmacol Sin. 2013 Nov;34(11):1374-80
pubmed: 24122008
Oncogene. 2017 Apr 6;36(14):1925-1938
pubmed: 27694892
Nat Med. 2005 Jul;11(7):712-4
pubmed: 16015356
Curr Pharm Biotechnol. 2014;15(5):429
pubmed: 25189575
Oncol Rep. 2018 Oct;40(4):1907-1916
pubmed: 30066897
Nat Rev Clin Oncol. 2010 Mar;7(3):163-72
pubmed: 20101258
Oncotarget. 2016 Jul 5;7(27):41575-41583
pubmed: 27223429
Tumour Biol. 2016 Oct;37(10):14249-14257
pubmed: 27571739
Cell Death Dis. 2017 Oct 26;8(10):e3154
pubmed: 29072689
Biochem Biophys Res Commun. 2014 Jan 31;444(1):1-5
pubmed: 24388989
Cancers (Basel). 2010 Aug 18;2(3):1617-28
pubmed: 24281177
Lancet. 2015 Mar 28;385(9974):1206-18
pubmed: 25479696
Biomed Pharmacother. 2018 Jul;103:782-789
pubmed: 29684857
Neoplasma. 2017;64(3):358-366
pubmed: 28253715
Front Biosci (Landmark Ed). 2013 Jan 01;18:734-9
pubmed: 23276957
Oncol Res. 2016;24(5):371-380
pubmed: 27712594
PLoS One. 2017 Oct 10;12(10):e0185565
pubmed: 29016617
JAMA. 2014 Jan 22-29;311(4):392-404
pubmed: 24449318
Cancer Med. 2016 Apr;5(4):693-702
pubmed: 26864640
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438
Sci Rep. 2017 Feb 01;7:38232
pubmed: 28145431
Cancer Res. 2019 Feb 1;79(3):572-584
pubmed: 30482773
Indian J Med Res. 2013 Apr;137(4):680-94
pubmed: 23703335
Acta Biochim Biophys Sin (Shanghai). 2016 Dec;48(12):1085-1093
pubmed: 27797718
Cell Physiol Biochem. 2017;44(5):1867-1881
pubmed: 29224010

Auteurs

Xin Sui (X)

Department of General Surgery, The people's Hospital of Danyang, Affiliated Danyang Hospital of Nantong University, No. 2, Xinmin RD, Danyang 212300, Jiangsu Province, China.

Zhenghui Sui (Z)

Department of General Surgery, The people's Hospital of Danyang, Affiliated Danyang Hospital of Nantong University, No. 2, Xinmin RD, Danyang 212300, Jiangsu Province, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH